Thomas Blaettler

Thomas Blaettler has a strong background in the pharmaceutical industry, with extensive experience in clinical development and medical roles. Thomas is currently serving as the Head of Global Clinical Development at Vectura Fertin Pharma since May 2023. Prior to this, they worked as the Chief Medical Officer at Coave Therapeutics from November 2021 to April 2023. Thomas also held the position of Chief Medical Officer at Orphazyme A/S from November 2016 to October 2021.

Before joining Orphazyme A/S, Thomas worked at Roche in various medical leadership positions. Thomas served as the PD Group Medical Director for Neuroscience and Global Development Leader for Olesoxime from May 2015 to October 2016. Before that, they were the PD Group Medical Director and leader of PD Neuroscience Development Integration from December 2013 to May 2015. Thomas also held the role of PD Associate Group Medical Director for Neuroscience and Global Development Team Leader for Bitopertin from April 2009 to December 2013.

Prior to their tenure at Roche, Thomas was a Medical Director at Bristol-Myers Squibb from February 2007 to March 2009. Thomas also worked as a Translational Medicine Expert II at Novartis from January 2004 to January 2007. Through these roles, Thomas has gained a wealth of knowledge and expertise in the field of clinical development and medical affairs.

Thomas Blaettler attended the University of Zurich from 1988 to 1994, where they obtained an MD degree in Medical School.